**Appendix Table D38. Risk of bias in randomized controlled clinical trials that examined dose response effectiveness of drugs for migraine prevention in children**

| **Reference** | **Masking of treatment status** | **Intention to treat analysis preplanned** | **Allocation concealment** | **Adequacy of randomization** | **Selective outcome reporting** | **Risk of bias** |
| --- | --- | --- | --- | --- | --- | --- |
| Winner, 200615 | Double-blind | Yes | Clearly adequate (computer-generated randomization schedule) | Not adequate (Topiramate 100mg had higher mean frequency and days of migraine compared to other groups and topiramate 200mg had higher percentage of men and women compared to other groups) | Unclear | Low |
| Lewis, 200716 | Double-blind | Yes | Unclear | Adequate | Unclear | Low |
| Apostol, 20085 U.S. Food and Drug Administration, 20086 | Double-blind | Yes | Unclear | Adequate | Unclear | Low |
| Lewis, 20097 | Double-blind | Yes | Clearly adequate | Adequate | Unclear | Low |
| Pandina, 201017 | Double-blind | Yes | Not reported | Adequate | Unclear | Low |